Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Multicenter, Parallel-Controlled Clinical Study on the Use of Huaier Granules for the Treatment of Bevacizumab- and Anlotinib-Related Proteinuria in Lung Cancer Patients

NCT07358520 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT07358520
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07358520 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Multicenter, Parallel-Controlled Clinical Study on the Use of Huaier Granules for the Treatment of Bevacizumab- and Anlotinib-Related Proteinuria in Lung Cancer Patients
Lead sponsor
Fudan University
Phase
Phase 4
Overall status
Not yet recruiting
Start date
January 28, 2026
Completion date
January 28, 2028
Enrollment
40 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

proteinuria